OpenAlex
PricingAboutJobs
Log inGet started
Work

A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR)

HTML

Year: 2006
Type: conference-abstract
Source: Journal of Clinical Oncology
DOI: 10.1200/jco.2006.24.18_suppl.7020
Authors: L. Paz-Ares, J. M. Sanchez, A. García-Velasco, B. Massuti, G. López-Vivanco, M. Provencio, A. Montes, D. Isla, M. L. Amador, R. Rosell
Institutions: Hospital de Cruces, Hospital General Universitario de Alicante Doctor Balmis, Hospital Universitari Germans Trias i Pujol
Language: English

Topic: Lung Cancer Treatments and Mutations
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Keywords: erlotinib, non-small cell lung cancer, EGFR mutation, tyrosine kinase inhibitors, exon 19 deletion, L858R mutation, T790M mutation, predictive biomarkers, monotherapy, treatment response, drug toxicity, treatment-naive patients
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W128476255
Cites:
Cited by: 169
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms